Dr. Luke Discusses the Combination of Epacadostat and Pembrolizumab in Melanoma

Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

In an interview with Targeted Oncology, Meredith McKean, MD, MPH of Sarah Cannon Research Institute reviewed the recent changes to the U.S. Preventive Services Task Force skin cancer screening guidelines, and discussed advances in the skin cancer treatment paradigm for those who could not prevent the disease.

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, and participants discussed the case of a 73-year-old man with a history of melanoma whose disease is now metastatic.

The proportion of patients with myelodysplastic syndromes who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for patients given roxadustat vs 33.3% for patients given placebo for the treatment of anemia.